Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Aug 17;20(10):591. doi: 10.1038/s41577-020-00431-9

A cocktail of antibodies for COVID-19 therapy

Dean B Matthews 1,
PMCID: PMC7430094  PMID: 32807860

Treatment of infectious disease with single monoclonal antibodies (mAbs) can exert a selective pressure that potentially increases the possibility of mutational escape of the targeted antigen. This risk can be reduced through the combination of multiple mAbs targeting non-overlapping epitopes. In this preprint, Baum et al. show the protective effects of REGN-COV2, a cocktail of two fully humanized mAbs that bind to different regions of the SARS-CoV-2 spike protein. Rhesus macaques and golden hamsters treated with REGN-COV2 have markedly lower levels of detectable sub-genomic viral mRNA in both prophylactic and therapeutic settings. In rhesus macaques, the mRNA decrease is evident in oral and nasopharyngeal swabs, as well as in bronchoalveolar lavage. Combined-phase clinical trials for REGN-COV2 are underway.

Competing interests

The author declares no competing interests.

References

Original article

  1. Baum A, et al. REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. bioRxiv. 2020 doi: 10.1101/2020.08.02.233320. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES